A carregar...
Silencing KIF14 reverses acquired resistance to sorafenib in hepatocellular carcinoma
For nearly a decade, sorafenib has served as a first-line chemotherapeutic drug for the treatment of hepatocellular carcinoma (HCC), but it displays only limited efficacy against advanced drug-resistant HCC. Regorafenib, the first second-line drug approved for treatment after sorafenib failure, can...
Na minha lista:
| Publicado no: | Aging (Albany NY) |
|---|---|
| Main Authors: | , , , , , , , |
| Formato: | Artigo |
| Idioma: | Inglês |
| Publicado em: |
Impact Journals
2020
|
| Assuntos: | |
| Acesso em linha: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7746348/ https://ncbi.nlm.nih.gov/pubmed/33203790 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.18632/aging.104028 |
| Tags: |
Adicionar Tag
Sem tags, seja o primeiro a adicionar uma tag!
|